Prostate Cancer

US Defense Secretary Lloyd Austin Transfers Duties To Deputy Amid Hospitalization For 'Emergent Bladder Issue'
Pentagon Faces Backlash For Keeping Defense Secretary Lloyd Austin's Prostate Cancer Diagnosis Secret From President Biden
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
Pentagon Faces Backlash For Keeping Defense Secretary Lloyd Austin's Prostate Cancer Diagnosis Secret From President Biden
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
ViewRay's MRI-Guided Stereotactic Body Radiotherapy Shows Favorable Toxicity Profile In Prostate Cancer
IsoRay's Cesium-131 Radiation Therapy Shows Favorable Outcomes In Prostate Cancer

Prostate Cancer Recent News

ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Data were presented at AACR-NCI-EORTC.
ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617.
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
MacroGenics Inc (NASDAQ: MGNX) 
Johnson & Johnson's Prostate Cancer Drug Erleada Wins NICE Approval
Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors
The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy.
Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy
Harpoon Therapeutics Stock Drops After Prostate Cancer Candidate Shows Cytokine-Related Adverse Events
Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals
Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
ImmunityBio's Prostate Cancer Vaccine Shows Early Signs Of Clinical Activity, Durable Stable Disease
ImmunityBio Inc (NASDAQ: IBRX) 
Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study
Novartis AG (NYSE: NVS) says that its Phase 3 VISION study of 177Lu-PSMA-617 
Cardiff Oncology's Onvansertib Combo Associated With Two-Fold Increase Disease Control Rate In Prostate Cancer Study
Janssen's Erleada Plus, Zytiga Plus Prednisone Combo Treatment Shows Clinical Benefit In Late-Stage Prostate Cancer Study
Poseida Shares Tank 34.5% As Prostate Cancer Drug Trial Halted After Patient's Death
Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with the United States Securities and Exchange
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Medivation Up As Triple M&A Interest Rumor Circulates
EXCLUSIVE: VolitionRX's New Cancer Diagnostic Could Mean No More Invasive Colonoscopies
Dendreon CEO On The Life-Extending Effects Of Provenge (DNDN)